Children's National - NIAID Partnership


About the Children's National - NIAID Partnership

In 2017, The National Institute of Allergy and Infectious Diseases (NIAID) and Children’s National Hospital launched a clinical research partnership devoted to protecting and advancing the health of children with allergic, immunologic, auto-inflammatory, and infectious disease through collaborative research and education. This strategic and novel alliance is supported through the CTSI-CN. The partnership, co-led by H. Clifford Lane, M.D., Deputy Director for Clinical Research and Special Projects at NIAID, and Mark Batshaw, M.D., Executive Vice President and Chief Academic Officer at Children’s National, holds the mission to generate and apply knowledge to promote the prevention, diagnosis, treatment, and cure of these childhood diseases through its work together.

For each area, designated investigators from each institution are collaborating to design and conduct clinical research studies that will advance prevention strategies, diagnoses, treatments, and cures for the diverse range of pediatric diseases involving the immune system. Many of these studies will include children at high risk for complications related to their underlying disease or to experimental therapeutics and diagnostic tests they receive. Research participants will have the opportunity to be seen at both Children’s National and the NIH Clinical Center in Bethesda, Maryland. Together, the two institutions provide comprehensive, state-of-the-art pediatric clinical support, infrastructure, and research capacity. These resources protect the safety of children, ensure that they receive the highest quality of care, and offer them the opportunity to participate in cutting-edge clinical research. In addition, the partnership established joint training opportunities for physician-scientists interested in caring for these children while developing their research expertise in pediatric immunology, allergic, and infectious diseases.


Annual Children's National - NIAID Symposium

2022 Virtual Symposium

Details about the 5th Annual Symposium will be available soon!

2021 Virtual Symposium
CNH/NIAID Partnership

This annual symposium celebrates the partnership between Children’s National Hospital (CNH) and the National Institute of Allergy and Infectious Diseases (NIAID). Established in 2017, the CNH-NIAID partnership focuses on advancing the health of children with allergic, immunologic, and infectious diseases through collaborative research and education.

In 2021, the Symposium was held on Thursday, June 3rd and Friday, June 4th as a virtual event that highlighted research on COVID-19 and multisystem inflammatory syndrome in children (MIS-C), and the intersectionality of COVID-19, allergy, and immunology on the pediatric population. Keynote speaker pediatric neurologist and 73rd Governor of The Commonwealth of Virginia, Ralph Northam, spoke on the COVID-19 pandemic and strategies to reintroduce children into schools and sports.  


Projects

Primary Immunodeficiency Program

Protocol Title: Investigating the Mechanistic Biology of Immunodeficiency Disorders

This study investigates novel forms of primary immunodeficiency (PID) and to better define the natural history of both new and previously described forms of PID, including severe combined immunodeficiency (SCID), combined immunodeficiency, natural killer (NK) cell deficiency, and other disorders. Patients with clinical and/or laboratory evidence of PID will be recruited at Children's National and NIAID, and will provide one or more blood donations during the course of the study to enable immunologic and genetic investigations of immune pathways contributing to PIDs. These subjects will also be followed clinically to longitudinally assess the natural history of novel and known PIDs. Subjects will be followed over time with regard to their immunologic phenotype, clinical disease (including incidence of infections, autoimmune phenomena, allergic disease, or malignancies), and response to both preventative and definitive therapies. Biological relatives who do not have PID and healthy adult volunteers will also be eligible to serve as controls for this study.

Food Allergy Program

Protocol Title: Natural History and Mechanistic Investigation of Atopic Disease in Childhood

The prevalence of atopic and allergic diseases has increased both in developed and developing countries in recent decades. Atopic diseases typically manifest in early childhood, progress through the first decade of life through what has become known as the ‘atopic march’ and then often persist throughout one’s lifetime. This study will investigate the natural history of a/the peanut allergy in a cohort of food-allergic and food-sensitized infants and determine whether allergy and sensitization is attributable to differences in regulatory T and B cell frequency/function compared with non-allergic, age-matched controls.

Infectious Disease Program

Protocol Title: Characterization of Pediatric Lyme Disease: Clinical Manifestations, Long Term Outcome, Immune Response, and Prevalence of PTLDs

The protocol proposes two paired substudies designed to characterize the clinical manifestations and long-term outcomes among pediatric Lyme disease patients in the greater Washington, DC area. Substudy 1 will characterize the natural history and longterm clinical, quality of life, and cognitive outcome of pediatric patients diagnosed with early and late stage Lyme disease, including prevalence of Post-Treatment Lyme Syndrome (PTLDS) and Substudy 2 will compare clinical, behavioral, cognitive and(future) immunologic response profiles between patients with full recovery, PTLDS and healthy controls. We will assess timeframe for resolution of symptoms after appropriate treatment, estimate the prevalence of PTLDS among a diverse cohort of pediatric patients diagnosed with Lyme disease within the past decade, and obtain specimens for future studies to identify the immune response of patients with PTLDS compared to patients who fully recovered from Lyme disease and healthy controls, as well as recently diagnosed patients with different manifestations of Lyme disease (early localized, disseminated, and late disease). Results of these analyses will be used to identify profiles and biomarkers that correlate with the outcome phenotypes. This signature could allow the design of a prognostic/diagnostic biomarker assays for patients with Lyme disease and PTLDS.

Neuro-Immune Program

A natural history protocol for the evaluation of patients with genetically defined or undifferentiated pediatric diseases characterized by inflammation of the central nervous system using advanced genetics and immunophenotyping is currently being developed. Affected participants will be clinically evaluated and provide biological samples for research. Leftover samples from clinical procedures may also be used for research. Genotyping, HLA typing and immunophenotyping will be performed free of charge. Follow-up visit may be scheduled on the basis of clinical status, with the aim of molecularly characterizing biologic samples including CSF in both active and quiescent states. Unaffected biological parents will provide biological samples to be used as controls.

Fellowship Training Programs

One of the overarching goals of the CNH-NIAID partnership is to provide joint training opportunities for investigators studying and caring for children with infectious, immunologic, and allergic diseases. To date, 12 exceptional fellows have matched and been placed into the training programs. In 2020, a formal career mentorship program and a protocol writing workshop with program officers from the NIH Division of Allergy, Immunology, and Transplantation (DAIT) was initiated to better prepare fellows for careers in academic medicine.